Minnesota is currently home to 2057 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
NCT03998202
Recruiting
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
04/02/2025
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Colorectal Cancer, Sarcopenia
Register for Updates
Visual Remapping to Aid Reading With Field Loss
NCT03848663
Recruiting
Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
04/02/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Age-related Macular Degeneration
Register for Updates
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
NCT06773910
Recruiting
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Minnesota Oncology Hematology, Maple Grove, Minnesota
Conditions: Limited Stage Small Cell Lung Cancer
Register for Updates
KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD-19 CAR T) Therapy, in Subject With Treatment Refractory Stiff Person Syndrome
NCT06588491
Recruiting
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Treatment Refractory Stiff Person Syndrome
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/01/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Stiff-Person Syndrome, SPS
Register for Updates
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247
Recruiting
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/01/2025
Locations: University of Minnesota Medical School - Twin Cities Campus, Minneapolis, Minnesota
Conditions: Leukemia
Register for Updates
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891
Recruiting
The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compared to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Lexicon Investigational Site (4027), Rochester, Minnesota
Conditions: Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Register for Updates
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357
Recruiting
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/01/2025
Locations: Research Site, Rochester, Minnesota
Conditions: Biliary Tract Cancer
Register for Updates
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288
Recruiting
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat and empagliflozin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Minneapolis VA Health Care System, Minneapolis, Minnesota
Conditions: Heart Failure
Register for Updates
Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors
NCT06322602
Recruiting
This observational trial evaluates the use of Ommaya reservoir placed during a biopsy to collect biomarkers longitudinally in patients with brain tumor. A biomarker is a measurable indicator of the severity or presence of the disease state. An Ommaya reservoir is a small device that's implanted under the scalp. It allows the doctor to take samples of cerebrospinal fluid (CSF) in the future without doing a spinal tap. The identification of biomarkers in CSF is rapidly emerging as a promising mini... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Brain Neoplasms
Register for Updates
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
NCT06212947
Recruiting
This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.
Gender:
ALL
Ages:
15 years and below
Trial Updated:
04/01/2025
Locations: University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota
Conditions: Hypochondroplasia
Register for Updates
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150
Recruiting
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: University Of Minnesota, Minneapolis, Minnesota
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
Automating Delirium Severity in the ICU
NCT06172491
Recruiting
The goal of this observational study is to develop a passive digital marker (PDM) for delirium severity and examine its performance in comparison to validated delirium severity tools in ICU patients \>50 years of age. The main questions it aims to answer are: * Is the trained convolutional neural network able to reliably measure delirium severity. * Is the Passive Digital Marker able to accurately measure delirium severity * Is the Passive Digital Marker acceptable and usable by frontline ICU... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/01/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Intensive Care Unit Delirium, Encephalopathy, Delirium
Register for Updates